Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

[Image: see text] Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CD...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Paruch, Kamil, Dwyer, Michael P., Alvarez, Carmen, Brown, Courtney, Chan, Tin-Yau, Doll, Ronald J., Keertikar, Kerry, Knutson, Chad, McKittrick, Brian, Rivera, Jocelyn, Rossman, Randall, Tucker, Greg, Fischmann, Thierry, Hruza, Alan, Madison, Vincent, Nomeir, Amin A., Wang, Yaolin, Kirschmeier, Paul, Lees, Emma, Parry, David, Sgambellone, Nicole, Seghezzi, Wolfgang, Schultz, Lesley, Shanahan, Frances, Wiswell, Derek, Xu, Xiaoying, Zhou, Quiao, James, Ray A., Paradkar, Vidyadhar M., Park, Haengsoon, Rokosz, Laura R., Stauffer, Tara M., Guzi, Timothy J.
Format: Artigo
Jezik:Inglês
Izdano: American Chemical Society 2010
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007794/
https://ncbi.nlm.nih.gov/pubmed/24900195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml100051d
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items